1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,060 | 4,080 | 24.10. | |
| 4,020 | 4,080 | 23.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Stage in Phase II First-Line Gastric Cancer Study | 1 | GlobeNewswire (USA) | ||
| Di | LEADS BIOLABS-B Phase II Study of Leadsin for First-line Gastric Cancer Treatment Enters Expansion Stage | 1 | AASTOCKS | ||
| Di | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PHASE II STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) AS FIRST-LINE TREATMENT FOR ... | - | HKEx | ||
| Mo | LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig and LBL-034 Featured in Six Abstracts at 2026 ESMO Congress | 1 | GlobeNewswire (USA) | ||
| Mo | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT ABSTRACTS OF SIX STUDIES PUBLISHED AT 2026 ESMO | 1 | HKEx | ||
| NANJING LEADS BIOLABS Aktie jetzt für 0€ handeln | |||||
| 16.10. | LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer | 1 | GlobeNewswire (USA) | ||
| 16.10. | LEADS BIOLABS-B First Patient Enrolled in Vilisin Combination Therapy Phase Ib/II Trial for Metastatic Colorectal Cancer | 2 | AASTOCKS | ||
| 16.10. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN PHASE IB/II CLINICAL TRIAL OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ... | 3 | HKEx | ||
| 12.10. | LEADS BIOLABS-B Says Vilastobart Granted FDA Fast Track Designation for First-line Treatment of Advanced Biliary Tract Cancer | 1 | AASTOCKS | ||
| 12.10. | LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer | 1 | GlobeNewswire (USA) | ||
| 12.10. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA ... | 1 | HKEx | ||
| 28.09. | LEADS BIOLABS CO., LTD.: Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition | 5 | GlobeNewswire (USA) | ||
| 28.09. | LEADS BIOLABS-B 's LBL-024 Granted Orphan Drug Designation in Japan | 1 | AASTOCKS | ||
| 28.09. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) GRANTED ORPHAN DRUG DESIGNATION IN JAPAN | 1 | HKEx | ||
| 23.09. | LEADS BIOLABS-B (09887): 2026 INTERIM REPORT | 1 | HKEx | ||
| 21.09. | LEADS BIOLABS CO., LTD.: Leads Biolabs' Pivotal Phase IIb Study of Opamtistomig (LBL-024) in Advanced EP-NEC Selected as ESMO 2026 Late-Breaking Abstract; Three Studies Selected for Proffered Paper Presentations | 6 | GlobeNewswire (USA) | ||
| 21.09. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PIVOTAL REGISTRATIONAL PHASE IIB STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) MONOTHERAPY ... | 1 | HKEx | ||
| 14.09. | LEADS BIOLABS CO., LTD.: WCLC 2026 | Leads Biolabs' Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First-Line NSCLC | 3 | GlobeNewswire (USA) | ||
| 14.09. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT UPDATED DATA FROM PHASE II CLINICAL STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) IN ... | - | HKEx | ||
| 31.08. | LEADS BIOLABS-B (09887): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 2 | HKEx |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,050 | +0,26 % | Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur | DJ Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur
DOW JONES--Der Finanzinvestor EQT will einem Agenturbericht zufolge den Diagnostikspezialisten Qiagen übernehmen. Wie... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,360 | +0,09 % | Wedbush raises Tango Therapeutics stock price target on trial data | ||
| COGENT BIOSCIENCES | 31,210 | 0,00 % | If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today | ||
| SUMMIT THERAPEUTICS | 15,470 | 0,00 % | Akeso, Inc.: Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer | Becomes the 7th International Registrational Clinical Trial for Ivonescimab
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026
HONG... ► Artikel lesen | |
| MODERNA | 178,42 | -0,19 % | Apple ein sicherer Hafen: Moderna: Kurseinbruch | Bloom: Rücksetzer ausnutzen? | Telekom: Starlink-Panik | Die Deutsche Telekom steht mal wieder unter Druck. SpaceX verhandelt wohl über den Zugang zu 80.000 Mobilfunkmasten in den USA. Damit dürfte wohl für T-Mobile, AT&T und Verizon die Konkurrenz deutlich... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 76,73 | 0,00 % | AstraZeneca, Cardiol Therapeutics, Kiniksa - Neue Hoffnung für Herzpatienten | Herz-Kreislauf-Erkrankungen gehören weltweit zu den größten medizinischen Herausforderungen. Während etablierte Pharmakonzerne Milliarden in neue Wirkstoffe und Künstliche Intelligenz investieren, entwickeln... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 27,200 | 0,00 % | Biotech Stocks At 52-Week Highs - Amylyx Pharmaceuticals +63% With Phase 3 Data, Vogenx +25%, Orchestra BioMed +19%, AtriCure, Charles River Laboratories | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 18, 2026, primarily driven by positive quarterly reports.Amylyx Pharmaceuticals Inc. (AMLX)Amylyx Pharmaceuticals... ► Artikel lesen | |
| LYCIA THERAPEUTICS | 29,560 | -1,47 % | Lycia Therapeutics Prices Upsized $317.5 Mln IPO At $18/Share | WASHINGTON (dpa-AFX) - Lycia Therapeutics Inc. (LYCA) a clinical-stage biotechnology company developing treatments for autoimmune, inflammatory, and allergic diseases, said Thursday it priced... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 41,520 | 0,00 % | H.C. Wainwright hebt Kursziel für Enliven Therapeutics auf 73 $ an | ||
| PRAXIS PRECISION MEDICINES | 252,88 | -0,03 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 21,010 | +0,05 % | ArriVent to present phase 1 data for ARR-217 at ESMO | ||
| BOLT BIOTHERAPEUTICS | 6,250 | -0,32 % | Bolt Biotherapeutics, Inc. - 8-K, Current Report | ||
| TRAVERE THERAPEUTICS | 50,05 | 0,00 % | Biotech Stocks At 52-Week Highs - Bioventus, Travere Therapeutics, Odyssey Therapeutics, Charles River Laboratories Climb With Q2 Results, Aclaris Therapeutics | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 5, 2026, primarily driven by positive quarterly reports.Bioventus Inc. (BVS)Bioventus is a medical device... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,100 | -0,08 % | Harmony Biosciences: Mizuho bekräftigt Einstufung nach Verhandlungen im Patentrechtsstreit | ||
| RECURSION PHARMACEUTICALS | 3,695 | -0,14 % | Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast |
Das Unternehmen NANJING LEADS BIOLABS CO LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,960 Euro und damit -1,98 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANJING LEADS BIOLABS CO LTD finden Sie auf Wallstreet Online.